Agile Therapeutics (NASDAQ:AGRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report sent to investors on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Stock Performance

Shares of AGRX stock opened at $1.46 on Friday. Agile Therapeutics has a 12-month low of $0.20 and a 12-month high of $2.63. The firm’s 50 day moving average is $1.24 and its 200 day moving average is $0.81. The stock has a market capitalization of $9.99 million, a P/E ratio of -0.40 and a beta of 1.58.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter. The firm had revenue of $5.58 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC raised its holdings in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the quarter. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.